주요우울장애(MDD) : 8개 시장의 의약품 예측과 시장 분석 - 업데이트판(2025년)
Major Depressive Disorder: Eight-Market Drug Forecast and Market Analysis - Update (2025)
상품코드
:
1688984
리서치사
:
GlobalData
발행일
:
2025년 03월
페이지 정보
:
영문 118 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
2019년 MDD 치료제 매출은 8개 주요 시장 전체에서 약 47억 3,000만 달러에 달했습니다. 미국 시장은 많은 MDD 환자 인구와 높은 약값으로 인해 세계 전체 매출의 대부분인 33억 5,000만 달러(70.7%)를 차지했고, 2029년까지 약 95억 5,000만 달러에 달할 것으로 예상되며, 연평균 7.3% 성장할 것으로 전망됩니다. 미국은 2029년에도 시장 선두를 유지하며 세계 매출의 84.7%를 차지할 것으로 예상됩니다.
예측 기간 동안 주요 8개 시장의 MDD 시장의 주요 성장 촉진요인은 다음과 같습니다.
제네릭 의약품의 접근성이 높은 가장 일반적으로 사용되는 MDD 치료제의 비용에 비해 치료 비용이 크게 높은 6개의 새로운 파이프라인 제품이 8개 주요 시장에서 출시될 예정임.
8개 주요 시장에서 12개월 동안 MDD의 총 유병자 수는 예측 기간 동안 증가할 것으로 예상됩니다.
세계 주요 8개국(미국, 유럽 5개국, 일본, 캐나다)의 주요 주요 우울장애(MDD) 시장에 대해 조사했으며, 질환 개요, 시장 매출 및 예측, 파이프라인 분석, 현재 및 향후 경쟁 구도 분석 등의 정보를 전해드립니다.
목차
표 리스트
도표 리스트
제1장 주요우울장애(MDD) : 주요 요약
- MDD 치료제 시장은 2029년까지 95억 달러에 이를 전망
- 주요 기업은 경쟁력 유지에 고전할 것으로 예상
- 우수한 효능과 신속한 작용 발현은 MDD 시장 가장 임박한 미충족 요구이다
- 새로운 후기 단계 파이프라인 의약품이 주요 성장요인
- 의사의 생각
제2장 서론
제3장 질환 개요
- 병인과 병태생리학
- 병분류 시스템
- 예후
- 삶의 질
제4장 역학
- 질환 배경
- 위험 요인과 합병증
- 세계의 과거 동향
- 예측 방법
- MDD 역학적 예측(2019-29년)
- MDD 12개월간의 총 유병자 수
- MDD 12개월간의 총 유병자 수 : 연령별
- MDD 12개월간의 총 유병자 수 : 성별
- MDD 12개월간의 총 유병자 수 : 18세 미만 중증도별
- 논의
- 역학적 예측 인사이트
- COVID-19의 영향
- 분석의 한계
- 분석의 강점
제5장 질병 관리
- 진단과 치료 개요
- 질병 관리에 관한 KOL(Key Opinion Leader)의 견해
제6장 경쟁 평가
제7장 미충족 요구와 기회 평가
- 개요
- 신속한 작용 발현
- 보다 효과 높은 새로운 치료법
- 안전성 프로파일이 개량
- 환자 결과 예상 관리
제8장 연구개발 전략
- 개요
- 새로운 MOA
- 보조 요법 개발
- 디지털 치료
- 맞춤형 치료/바이오마커
- 임상시험 디자인
제9장 파이프라인 평가
제10장 파이프라인 평가 분석
제11장 현재와 향후 기업
제12장 시장 전망
제13장 부록
LSH
영문 목차
This report covers the 8 major markets and provides an Excel-based forecast model for the Major Depressive Disorder market through 2029.
GlobalData estimated that drug sales for MDD in 2019 were approximately $4.73 billion across the 8MM. The US market makes up the majority of total global sales, contributing $3.35 billion (70.7%) due to the large MDD prevalent population, combined with the high price of medication in the country. GlobalData anticipates that the MDD market will grow to be worth approximately $9.55 billion by 2029, at a compound annual growth rate (CAGR) of 7.3%. The US is expected to maintain its position as the market leader in 2029, increasing the proportion of global sales it accounts for to 84.7%
The major drivers of growth in the MDD market in the 8MM over the forecast period include:
The launch of six new pipeline products throughout the 8MM, which will have significantly higher costs of therapy when compared with the cost of the most commonly used MDD treatments that have high generic availability.
In the 8MM, the number of 12-month total prevalent cases of MDD is expected to increase during the forecast period.
Scope
- Overview of major depressive disorder (MDD), including epidemiology, symptoms, diagnosis, and disease management.
- Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2019 to 2029.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 8MM MDD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM MDD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
Table of Contents
List of Tables
List of Figures
1 Major Depressive Disorder: Executive Summary
- 1.1 MDD therapeutics market will grow to $9.5 billion by 2029
- 1.2 Key players will struggle to maintain their competitive position
- 1.3 Better efficacy and rapid onset of action are the most pressing unmet needs in the MDD market
- 1.4 Novel late-stage pipeline drugs will be a key driver of growth
- 1.5 What do physicians think?
2 Introduction
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
3 Disease Overview
- 3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
- 3.2 Disease staging systems
- 3.3 Prognosis
- 3.4 Quality of life
4 Epidemiology
- 4.1 Disease background
- 4.2 Risk factors and comorbidities
- 4.3 Global and historical trends
- 4.4 Forecast methodology
- 4.4.1 Sources used
- 4.4.2 Sources not used
- 4.4.3 Forecast assumptions and methods
- 4.4.4 Forecast assumptions and methods: 12-month total prevalence of MDD
- 4.4.5 Forecast assumptions and methods: 12-month total prevalence of MDD by severity
- 4.5 Epidemiological forecast for MDD (2019-29)
- 4.5.1 12-month total prevalent cases of MDD
- 4.5.2 Age-specific 12-month total prevalence of MDD
- 4.5.3 Sex-specific 12-month total prevalent cases of MDD
- 4.5.4 12-month total prevalent cases of MDD by severity for ages <18 years
- 4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis
5 Disease Management
- 5.1 Diagnosis and treatment overview
- 5.2 KOL insights on disease management
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 Rapid onset of action
- 7.3 New therapies with better efficacy
- 7.4 Improved safety profiles
- 7.5 Management of patient outcome expectations
8 R&D Strategies
- 8.1 Overview
- 8.1.1 Novel MOAs
- 8.1.2 Development of adjunctive therapies
- 8.1.3 Digital therapeutics
- 8.1.4 Personalized treatments/biomarkers
- 8.2 Clinical trials design
- 8.2.1 Study design
- 8.2.2 Endpoints
- 8.2.3 Placebo response rate
9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
- 10.1 Overview
- 10.2 Competitive assessment
- 10.2.1 Monotherapies
- 10.2.2 Adjunctive therapies
11 Current and Future Players
- 11.1 Overview
- 11.2 Deal-making trends
12 Market Outlook
- 12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
- 12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
- 12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
- 12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers
- 12.5 Canada
- 12.5.1 Forecast
- 12.5.2 Key events
- 12.5.3 Drivers and barriers
13 Appendix
- 13.1 Bibliography
- 13.2 Abbreviations
- 13.3 Methodology
- 13.3.1 Forecasting methodology
- 13.4 Primary research - KOLs interviewed for this report.
- 13.5 Primary research - prescriber survey
- 13.6 About the authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Managing Epidemiologist
- 13.6.5 Vice President of Disease Intelligence and Epidemiology
- 13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence
- About GlobalData
- Contact Us
관련자료
